MedTrace Logo

The IDEAL-PCI Extended Registry

NCT02974777 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer).

IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit

Conditions

  • Coronary Arterioscleroses
  • Platelet Dysfunction Due to Drugs

Interventions

DRUG

DAPT reduction

Reduction of standard dose DAPT due to low platelet reactivity

DRUG

DAPT on-target

Standard DAPT within the therapeutic window of platelet reactivity

DRUG

DAPT intensification

Intensification of standard dose DAPT due to high platelet reactivity

Sponsors & Collaborators

  • Kaiser Franz Josef Hospital

    lead OTHER

Principal Investigators

  • Guenter Christ, MD · Kaiser Franz Josef Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974777 on ClinicalTrials.gov